文献速递中医内科中药与中成药合理使用

中草药联合生物药治疗特发性膜性肾病的系统评价与网状Meta分析

Efficacy and safety of Chinese herbal medicines combined with biomedicine in the treatment of idiopathic membranous nephropathy: a systematic review and network meta-analysis.
PubMed 文献 · Front Pharmacol · 2024-10-30

该系统评价与网状Meta分析检索多个中英文数据库至2024年5月31日,纳入31项RCT共2195例特发性膜性肾病患者,比较15种中草药联合生物药(BM)的疗效与安全性;结果显示不同中草药联合方案在降低24小时尿蛋白、提升血清白蛋白、改善血肌酐、降低总胆固醇与甘油三酯及减少不良反应方面各具优势,但受纳入研究数量与质量限制,结论尚需进一步验证。

要点

  • QQC+BM在降低24小时尿蛋白方面概率排名最高(84.7%)。
  • HZC+BM提升血清白蛋白最优(86%),WZC+BM不良反应率最低(90.8%)。
  • MXC+BM降甘油三酯(97%)与总胆固醇(89%)最优,LGT+BM改善血肌酐最佳(77.2%)。

核心结论

  • 中草药联合生物药治疗特发性膜性肾病可能带来显著获益。
  • 不同中草药联合方案在降低24小时尿蛋白、提升血清白蛋白、改善血肌酐、降低血脂及减少不良反应方面各具相对优势。
  • 受纳入研究数量与质量限制,上述结论需进一步验证。

研究设计与样本

  • 系统评价与网状Meta分析,检索PubMed、EMBASE、Web of Science、Cochrane Library、CNKI、万方、维普及CBM数据库至2024年5月31日。
  • 纳入31项随机对照试验(RCT),共2195例特发性膜性肾病患者,涉及15种中草药。
  • 由两名研究者独立筛选文献与提取数据,采用Cochrane质量评价手册评估质量,使用Stata 14.2软件进行网状Meta分析。

主要发现

  • 降低24小时尿蛋白方面,QQC+BM概率排名最高(84.7%)。
  • 提升血清白蛋白方面,HZC+BM概率排名最高(86%)。
  • 改善血清肌酐方面,LGT+BM概率排名最高(77.2%)。
  • 降低总胆固醇(89%)与甘油三酯(97%)方面,MXC+BM概率排名最高。
  • 减少不良反应发生率方面,WZC+BM概率排名最高(90.8%)。

关键数值与推荐

  • QQC+BM降低24小时尿蛋白的概率排名为84.7%。
  • HZC+BM提升血清白蛋白的概率排名为86%。
  • LGT+BM改善血清肌酐的概率排名为77.2%。
  • MXC+BM降低总胆固醇与甘油三酯的概率排名分别为89%与97%。
  • WZC+BM减少不良反应发生率的概率排名为90.8%。

临床怎么用

  • 临床可结合患者主要临床问题(蛋白尿、低白蛋白血症、肾功能、血脂或不良反应风险)参考相应概率排名最高的中草药联合方案。
  • 应用上述联合方案时需结合患者个体情况与药物可及性,并关注不良反应监测。
  • 因证据质量有限,不宜将概率排名直接作为强推荐依据,需结合临床经验与患者意愿决策。

局限性

  • 纳入研究的数量与质量存在局限性,可能影响结论可靠性。
  • 结论需进一步通过高质量研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chinese herbal medicines have been extensively used to treat idiopathic membranous nephropathy (IMN). However, their efficacy and safety remain uncertain. Therefore, this study employed a network meta-analysis to evaluate the efficacy and safety of various Chinese herbal medicines in combination with biomedicines for treating IMN. METHODS: A comprehensive literature search was performed across several databases, including PubMed, EMBASE, Web of Science, Cochrane Library, China National Knowledge Infrastructure (CNKI), WanFang Data, VIP Database, and Chinese Biomedical Literature Database (CBM), to identify randomized controlled trials (RCTs) concerning the treatment of IMN using a combination of Chinese herbal medicines and biomedicine, up to 31 May 2024. Two researchers independently conducted the literature screening and data extraction. The quality of the included studies was assessed using the Cochrane quality review manual, and Stata 14.2 software was employed for network meta-analysis. RESULTS: A total of 31 RCTs involving 2195 IMN patients and 15 different Chinese herbal medicines were analyzed. The network meta-analysis revealed that QQC + BM (84.7%) was the most effective in reducing 24-hour urinary protein. For improving serum albumin, HZC + BM (86%) was the most effective. LGT + BM (77.2%) was the best for enhancing serum creatinine levels. MXC + BM demonstrated the highest effectiveness in lowering total cholesterol (89%) and triglycerides (97%). Lastly, WZC + BM (90.8%) was the most effective in reducing the incidence of adverse reactions. BM. CONCLUSION: The current evidence suggests that integrating Chinese herbal medicines with biomedicine may provide significant benefits in treating IMN. Specifically, QQC + BM appears to be the most effective in reducing 24-hour urinary protein, HZC + BM seems to excel in improving serum albumin levels, MXC + BM is noted for its effectiveness in lowering triglycerides and total cholesterol, LGT + BM is optimal for reducing serum creatinine, and WZC + BM shows the lowest rate of adverse reactions. Nevertheless, due to limitations in the quantity and quality of the included studies, further validation of these conclusions is necessary. SYSTEMATIC REVIEW REGISTRATION: [https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024561028], identifier [CRD42024561028].

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Zhu H, Xiao Y, Ji Y, et al. Efficacy and safety of Chinese herbal medicines combined with biomedicine in the treatment of idiopathic membranous nephropathy: a systematic review and network meta-analysis. Front Pharmacol. 2024. PMID: 39539621. doi:10.3389/fphar.2024.1391675

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。